Ampersand is a venture capital firm that focuses on investing in and accelerating growth for healthcare entrepreneurs.

Ampersand

Founded in 1988, Ampersand is a middle-market private equity firm with $3 billion of assets under management dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of the firm's core healthcare sectors. 

Consistent with our theme of increasing specialization as a source of differentiated performance, Ampersand’s Healthcare portfolio has been focused around several overlapping industry clusters where our multiple prior successes give us a competitive edge. Most of our portfolio companies have revenues between $10 and $200 million at the time of Ampersand’s investment. We typically invest between $10 and $200 million and years of operational expertise to drive each investment toward success.

Ampersand’s team has decades of operating experience in Healthcare companies and over 150 years of shared private equity experience. Our unusual combination of skills, including deep industry, technical, financial, operating, and transactional capabilities, make us a preferred partner for entrepreneurs because we can contribute to their success on multiple levels.

At our roots, we are company-builders, not investment managers. Our experience gives us empathy for our CEOs and helps us understand the challenges they face. This ability to identify, and contribute to, problem resolution makes us very effective in our companies.

Azurity Pharmaceuticals

Endeca

FirstRain

GENEWIZ

Nexcelom Bioscience

Genome Diagnostics

Avista Pharma

Bako Diagnostics

Bioventus

Blue Sky Biotech

LakePharma

Magellan Diagnostics

Brammer Bio

Canopy Biosciences

Ampersand Capital Partners

Shoutout to our incredible Ampersand Capital Partners team and all the financial services companies who came together for the 2024 Boston YPEM Cornhole Classic! 🎉 While our Ampersand colleagues may not have made the podium, the event was a huge success, raising over $20,000 to support Expect Miracles Foundation - Financial Services Against Cancer in providing crucial financial assistance to young cancer survivors. 🙌
A big thank you to everyone who donated to make a difference in the lives of others. #ExpectMiracles #CommunityImpact #TeamAmpersand

Ampersand Capital Partners is proud to be named a GrowthCap Top Private Equity Firm of 2024! We are grateful to our partners who helped make this recognition possible. For over 35 years, we believe our deep experience, strategic insight, and collaborative relationships with CEOs, management teams, and industry advisors have driven strong outcomes in the healthcare and life sciences companies in which we invest. This recognition reflects more than just financial success - it underscores our firm’s culture, growth, and commitment to creating long-standing value. See the press release and related disclaimer: https://lnkd.in/ewrcmhKn

Congratulations, Resolian, on being nominated for the Life Sciences Queensland Ltd (LSQ) 2024 GENE Award, Company of the Year!

Welcome, Shehnaz Jaffar Kataria, Chief Financial Officer of StageBio! “Shehnaz’s history of implementing progressive growth strategies will be a pivotal and valuable asset to the StageBio team,” shares David Bruning, President/CEO of StageBio.

Congratulations to Phosphorex , a leading drug delivery-focused CDMO and Ampersand Capital Partners portfolio company, on their strategic investment from NOF AMERICA CORPORATION. The partnership will accelerate the establishment of Phosphorex’s cGMP capabilities, paving the way for enhanced collaboration and innovation in nanoparticle-based drug delivery on a global scale.

Ampersand Capital Partners portfolio company iuvo BioScience has earned four impressive audit awards for their dedication to upholding the highest standards of excellence and compliance in clinical research and lab services.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 3, 2024 11:53 PM	9941f522
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 4, 2024 2:08 AM	e36551d9
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Sep 3, 2024 11:53 PM	783824cb
translate crunchbase fundingrounds	general
peers	general	Sep 3, 2024 11:53 PM	f36aece7
news basic	general	Sep 3, 2024 11:53 PM	8f11decd
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:AMPERSANDCAPITAL

Ampersand